Young children with cystic fibrosis treated with a combination of the CFTR-correcting therapies ivacaftor (Kalydeco) and lumacaftor (Orkambi) have seen rapid improvements in their symptoms in a phase III randomised controlled trial. The fixed dose combination treatment with lumacaftor (100mg) and ivacaftor (125mg) improved the lung clearance index (LCI2.5) and sweat chloride concentrations in 6-11 year olds, ...
Early combo treatment benefits kids with CF
By Mardi Chapman
12 Jun 2017